Brief: Tg Therapeutics Announces Data From The Ultimate I & Ii Phase 3 Trials Of Briumvi® (Ublituximab-Xiiy) In Multiple Sclerosis To Be Presented At The 2023 Consortium Of Multiple Sclerosis Centers Annual Meeting
31/05/2023 13:10
May 31 (Reuters) - TG Therapeutics Inc TGTX.O :
* TG THERAPEUTICS ANNOUNCES DATA FROM THE ULTIMATE I & II
PHASE 3
TRIALS OF BRIUMVI® (UBLITUXIMAB-XIIY) IN MULTIPLE SCLEROSIS TO
BE PRESENTED AT THE 2023 CONSORTIUM OF MULTIPLE SCLEROSIS
CENTERS ANNUAL MEETING
Source text for Eikon: ID:nGNX96KptD
Further company coverage: TGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj